Orum Therapeutics Inc
Company Profile
Business description
Orum Therapeutics Inc is a new drug development biotechnology company that develops anticancer drugs with the technology to attach novel drug payloads to ADC. It can develop all three components of ADC, which consist of antibodies, payloads, and linkers, in-house. The group pioneering a class of therapeutics intended to expand the universe of druggable targets and to meaningfully improve upon potency and tolerability, thereby improving the therapeutic window of drugs. Its services include the modeling, research, development, and testing of pharmaceuticals and treatments for such diseases for Orum’s partners and licensees. The pipeline products are TPD2GSPT1, TPD2PROTAb, and TPS2Cbl-b.
Contact
Munji-ro
281-25, 2nd floor
Yuseong-gu
Daejeon
KORT: +82 427163030
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
17
Stocks News & Analysis
stocks
Short-term pain for long-term gain for undervalued ASX share
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,010.10 | 117.10 | -1.28% |
| CAC 40 | 7,723.76 | 69.51 | 0.91% |
| DAX 40 | 23,627.49 | 140.16 | 0.60% |
| Dow JONES (US) | 45,210.14 | 85.67 | -0.19% |
| FTSE 100 | 9,159.54 | 42.85 | 0.47% |
| HKSE | 25,343.43 | 153.12 | -0.60% |
| NASDAQ | 21,545.74 | 266.11 | 1.25% |
| Nikkei 225 | 41,938.89 | 371.60 | -0.88% |
| NZX 50 Index | 13,074.81 | 58.35 | -0.44% |
| S&P 500 | 6,451.38 | 35.84 | 0.56% |
| S&P/ASX 200 | 8,738.80 | 120.20 | -1.36% |
| SSE Composite Index | 3,813.56 | 44.58 | -1.16% |